InMode is an international healthcare company with its headquarters in Yokneam, Israel. Founded in 2008, the company focusses on the design, development, and manufacture of minimally-invasive aesthetic medical products. Healthcare products developed by InMode harness novel radio frequency technology, and are based on its proprietary radiofrequency-assisted lipolysis and deep subdermal fractional radiofrequency technologies.
InMode trades on the NASDAQ GS under the ticker INMD. In 2020, the INMD price chart showed a 52-week low of $13.14 and a 52-week high of $58.76, with a market cap of $1.31bn. In September 2020 InMode announced approval for a share repurchase programme of up to 1 million ordinary shares.
The company produces state-of-the-art devices to support aesthetic treatments for the face, body and skin — including plastic surgery and dermatology — using mainly non-invasive and minimally-invasive options. InMode strives to use technology to enable new and emerging surgical procedures, and to improve existing treatments. The organisation mainly serves healthcare providers in various specialities across the globe, and regularly hosts seminars and attends conferences to raise awareness around its unique technologies.
Diversify your investment portfolio today by buying INMD stock. You can also track the INMD share price by adding this instrument to your eToro watchlist for instant updates.